<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>c69600ex99-1.txt
<DESCRIPTION>PRESS RELEASE DATED APRIL 30, 2002
<TEXT>
<PAGE>
                                                                    Exhibit 99.1

[SHEFFIELD PHARMACEUTICALS, INC. LOGO]


NEWS RELEASE

For further information contact:

THOMAS M. FITZGERALD
Sheffield Pharmaceuticals, Inc.
(585) 292-0310

FOR IMMEDIATE RELEASE

        SHEFFIELD PHARMACEUTICALS ANNOUNCES SENIOR MANAGEMENT CHANGES AND
                               NEW BOARD MEMBERS

ST. LOUIS, MO - APRIL 30, 2002 - Sheffield Pharmaceuticals, Inc. (AMEX:SHM)
today announced that Thomas M. Fitzgerald, former chairman has assumed the roles
of president and chief executive officer. John M. Bailey, board member since
1997, has assumed the role of chairman. Two new board members, Allan M. Fox and
Andrew J. Ferrara, were also appointed. Loren G. Peterson has stepped down as
president and chief executive officer of the Company and has also resigned as a
director, effective immediately, to pursue other interests.

     "The board of directors has asked me to be more involved in day-to-day
operations of the Company, and I am pleased to accept this challenge," said
Thomas Fitzgerald. "I welcome the opportunity to lead Sheffield in advancing our
exceptional pulmonary technologies. I am particularly pleased that John Bailey
has agreed to assume the position of non-executive chairman. He has been a
valued member of Sheffield's board since his election in 1997 and his
willingness to assume a greater role is important to Sheffield. Allan Fox and
Andrew Ferrara are life-long professionals in healthcare with a profound
understanding of today's industry, which will broaden the resources available to
our Company. I also want to thank Loren Peterson for his service to Sheffield."

     Mr. Fitzgerald joined Sheffield in 1996 and has previously served as chief
operating officer and president of Sheffield. He has been a member of the board
of directors of the Company since 1997. John M. Bailey, the new chairman, is
founder of Bailey Associates, a worldwide strategic advisory firm. Previously,
Mr. Bailey had been a member of the board of directors for Fisons plc and was
appointed Corporate Development Director with responsibility for worldwide
corporate strategic development. Allan M. Fox is founder of FoxKiser, a firm
specializing in identifying and enhancing business opportunities and improving
market position in the pharmaceutical and biotechnology industries. Mr. Fox had
also served as chief of staff and chief legislative assistant to former Senator
Jacob K. Javits of New York, and was chief counsel to the U.S. Senate Health and
Scientific Research Subcommittee, chaired by Senator Edward M. Kennedy. Andrew
J. Ferrara is founder and president of Boston Healthcare Associates, a
consulting firm that helps pharmaceutical and biotechnology companies achieve
their development and revenue objectives. Mr. Ferrara was with Eli Lilly &
Company for 20 years, most recently as corporate director of new product
planning and

                                     -more-
<PAGE>
                                       -2-


licensing. He was also co-founder and executive vice president of Polygen
Corporation, now Molecular Simulations, Inc., a computer software company
serving the pharmaceutical research and chemical industries.

     The Company also announced that Elan Corporation has elected not to
nominate a representative for the board of directors. Todd C. Davis, a partner
in Apax Partners, Inc., a leading international private equity investment group,
will remain on the board of directors as an independent non-executive director.
Mr. Davis has been a member of the board since 1998.

     Reporting to Mr. Fitzgerald are Scott A. Hoffmann, Sheffield's vice
president finance and administration and chief financial officer, and Thomas A.
Armer, Ph.D., Sheffield's chief scientific officer. Dr. Armer leads a team of
pulmonary drug delivery professionals who are responsible for the clinical and
regulatory development of Sheffield's product pipeline.

     "Sheffield's recent management changes will serve to position the Company
for maximum future growth," said Mr. Bailey. "We are confident that the new
senior management team led by Tom Fitzgerald and the appointment of additional
non-executive independent directors will lead Sheffield toward achieving
significant progress with its world-class pulmonary technology and outstanding
technical expertise."

     Sheffield has also retained two world-class professionals to participate in
the Company's clinical and regulatory efforts: Barry W. Steiger, M.D., formerly
of Astra-Zeneca, and Robert B. Parker, Ph.D. formerly of Celltech.

     Sheffield Pharmaceuticals, Inc. provides innovative, cost-effective
pharmaceutical therapies by combining state-of-the-art pulmonary drug delivery
technologies with existing and emerging therapeutic agents. Sheffield is
developing a range of products to treat respiratory and systemic diseases using
pressurized metered dose, solution-based and dry powder inhaler and formulation
technologies, including its proprietary Premaire(R) Delivery System and
Tempo(TM) Inhaler. Sheffield focuses on improving clinical outcomes with
patient-friendly alternatives to inconvenient or sub-optimal methods of drug
administration. Investors can learn more about Sheffield Pharmaceuticals on its
Web site at www.sheffieldpharm.com.


                                      # # #


     This press release contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, which are intended to be
covered by the safe harbors created thereby. Investors are cautioned that all
forward-looking statements involve risks and uncertainty. Although the Company
believes that the assumptions underlying the forward-looking statements
contained herein are reasonable, any of the assumptions could be inaccurate, and
therefore, there can be no assurance that the forward-looking statements
included in this press release will prove to be accurate. Important factors that
could cause actual results to differ materially from the forward-looking
statements include the Company's need to obtain substantial additional capital
(through financings or otherwise) to fund its operations and the progress of
development, government and regulatory approvals and licensing/commercialization
of the Company's technologies. In light of the significant uncertainties
inherent in the forward-looking statements included herein, the inclusion of
such information should not be regarded as a representation by the Company or
any other person that the objectives and plans of the Company will be achieved.

</TEXT>
</DOCUMENT>
